Preliminary results of early clinical trials with the fully human anti- TNFα monoclonal antibody D2E7

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Kempeni, Joachim ^a  

^a Knoll AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL RESEARCH; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HUMAN; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; RANDOMIZED CONTROLLED TRIALS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032705008     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Brooks P. Clinical management of rheumatoid arthritis. Lancet 1993;341:286-90.
2. Maini R, Brennan F, Williams R, et al. TNF-a in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol 1993;11 (suppl 8):S173-5.
3. Feldmann M, Brennan F, Chu C, et al. Does TNF-a have a pivotal role in the cytokine network in rheumatoid arthritis? In: Friers W, ed. Tumor necrosis factor: molecular and cellular biology and clinical relevance. Basel: Karger, 1993:144-52.
4. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36: 1681-90.
5. Scallon B, Moore M, Trinh H, Knight D, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7;251-9.
6. Rankin FC, Choy EH, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34:334-42.
7. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337;141-7.
8. Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:593-614.
9. Jespers L, Roberts A, Mahler S, Winter C, Hoogenboom H. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (NY) 1994;12:899-903.
10. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
11. Felson D, Anderson J, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical studies. Arthritis Rheum 1995;38:727-35.
12. van Gestel A, Prevoo M, Van'T Hoff M, et al. Development and validation of the European league Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40.
13. van de Putte L, van Riel P, den Broeder A, et al. A single dose placebo-controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1998;41 (suppl):57.
14. Rau R, Sander O, den Brooder A, et al. Long term efficacy and tolerability of multiple iv doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1998;41 (suppl):55.
15. Schattenkirchner M, Krüger K, Sander O, et al. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1998;41 (suppl):57.